FDA warned Body Good Studio over its website selling compounded semaglutide with a false claim that it matches Ozempic and Wegovy.
What happened
FDA reviewed Body Good Studio’s website at bodygoodstudio.com in August 2025. The site offered various compounded drug products, including semaglutide, and stated that compounded semaglutide is made of the same active ingredients as Ozempic and Wegovy. FDA said compounded drugs are not FDA-approved, so the statement is false or misleading and the products are misbranded.
What FDA found
The website claim that compounded semaglutide has the same active ingredients as Ozempic and Wegovy is false or misleading because compounded drugs are not FDA-approved.
FDCA sections 502(a) and 502(bb) [21 U.S.C. §§ 352(a), 352(bb)]These misbranded products were introduced or delivered for introduction into interstate commerce.
FDCA section 301(a) [21 U.S.C. § 331(a)]Receiving, delivering, or offering delivery of these misbranded drugs in interstate commerce is also prohibited.
FDCA section 301(c) [21 U.S.C. § 331(c)]
What FDA wants
FDA tells Body Good Studio to take immediate action, including ceasing the misleading claim, and to respond in writing within 15 working days describing specific corrective steps, how it will prevent recurrence, and supporting documentation.
Who should pay attention
- telehealth and online wellness brands selling compounded GLP-1 drugs
- compounding pharmacies and suppliers of compounded semaglutide
- marketing teams writing drug claims for websites
This is a summary. Read the original letter on fda.gov.